Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy

Panagiota Drivelegka 1*, Valgerdur Sigurdardottir 1, 2, Anna Svärd 2, Lennart T. H. Jacobsson 1 and Mats Dehlin 1

Abstract

Background: The aim of this study is to examine the occurrence of comorbidities at the time of first diagnosis of gout compared with matched population controls, overall and by sex, as well as to examine the crude and age-standardized prevalence of these comorbidities in men and women with gout at first diagnosis.

Methods: A population-based study used data from Swedish national and regional registers, including 14,113 gout patients aged ≥ 20 years, with a first recorded diagnosis of gout between 1 January 2006 and 31 December 2012, and 65,782 population controls, matched by age, sex and county. Prevalence ratios (95% confidence intervals) comparing gout cases and controls were calculated, overall and by sex. Crude and age-standardized prevalence (95% confidence interval) of all comorbidities in gout patients were calculated, to show differences between sexes, taking also the higher age at diagnosis in women into account.

Results: All examined comorbidities were 1.2–2.5-fold more common in gout patients at diagnosis than in population controls in both sexes. Women with gout were on average 6 years older than men at first gout diagnosis and most comorbidities, including obesity and diuretic use, were or tended to be more frequent in women than in men. When standardizing for age, women had a higher prevalence of thromboembolism (6.6% vs 5.2%) and chronic obstructive pulmonary disease (3.1% vs 2.4%). Men, on the other hand, had a higher prevalence of coronary heart disease (9.4% vs 6.4%), atrial fibrillation (9.0% vs 6.0%), congestive heart failure (7.7% vs 6.6%) and stroke (4.1% vs 3.3%).

Conclusions: The occurrence of most comorbidities was significantly increased at first diagnosis of gout in both sexes. Women were older at diagnosis and had higher occurrence of most comorbidities, including obesity and diuretic use, factors that increase serum urate, and this needs to be taken into account when starting and optimizing urate lowering therapy. These sex differences were attenuated when standardizing for age and the occurrence of cardiovascular diseases was actually higher in men.

Keywords: Gout, Comorbidity, Epidemiology, Gender, Urate lowering treatment
Background

Gout is the most common form of inflammatory arthritis and is caused by deposition of monosodium urate (MSU) crystals in peripheral joints and surrounding tissues as a result of chronic elevation of serum urate (SU) levels. The incidence and prevalence of gout are increasing in many parts of the world and the prevalence is >1% in North America and Europe [1].

Gout has been linked with an increased occurrence of several comorbidities, which all may influence the overall effect on quality of life and increased mortality [2–4]. Some of these comorbidities, such as use of diuretics [5, 6], renal disease [7–14], obesity [15, 16], transplantation [17–20], psoriasis [21, 22] and alcohol overconsumption [23, 24], have also been suggested to increase SU levels and hence be part of the causal pathway for developing hyperuricemia and clinical gout. Epidemiological studies examining the relationship between gout and risk for cardiovascular diseases (CVD) overall and in men and women separately report conflicting findings, with a significant association reported by some studies [3, 4, 25, 26], but not others [27–29]. There is only limited evidence for positive associations with cerebrovascular disease [30–33] or peripheral vascular disease (PVD) [34, 35].

Current clinical guidelines and management pathways endorsed by the European League against Rheumatism [36], American College of Rheumatology [37] and British Society for Rheumatology [38] agree on the importance of assessing comorbidities before deciding to initiate treatment of gout with urate lowering therapy (ULT). In addition, there are also results supporting the need for higher doses of ULT if patients have comorbid conditions, such as renal disease, use of diuretics or obesity [39]. This effect of decreased eGFR and diuretic use is probably explained by their ability to increase SU levels and not by any effect on the dose–response relationship between allopurinol dose and change in urate levels [40].

It is well known that several comorbidities occur more commonly in patients with gout compared to the general population [20, 41–43], although there are relatively few population representative studies from Europe [43]. Furthermore, the timing of comorbidity occurrence relative to gout diagnosis has not always been addressed. In particular, there are very few studies examining the prevalence of comorbidities in patients with gout by sex [44–47] and none of them have presented results at the time of gout diagnosis. If such differences between sexes were found, they could indicate that pathological pathways differ in importance in men and women. In addition, such differences could be of importance to take into consideration when initiating and dosing ULT [39].

Using healthcare register data in the Western Swedish Health Care Region (VEGA) to identify cases and population registers to identify matched controls, and linking these groups to several national registers, this study aimed to: examine the occurrence of several comorbidities at the time of first diagnosis of gout compared with matched controls, overall and by sex; and examine the crude and age-standardized prevalence of these comorbidities in men and women with gout at first diagnosis.

Methods

Study design

We conducted a population-based and register-based case–control study using register data from 1 January 2000 through 31 December 2012 comparing patients at the time of first gout diagnosis to matched general population controls.

Ethical approval for the study was granted from the Ethical Review Board of Gothenburg, Sweden. Informed consent from the patients was not needed as the study only involved quality register linkage and no actual handling of patients.

Setting

According to Statistics Sweden, in 2016 the population of Sweden was 9,995,153 and in Västra Götaland, a county in the western part of Sweden, where the study was conducted, the population was 1,671,783 (http://www.scb.se/hitta-statistik/statistik-efter-amne/befolkning/befolkningens-samtalnsattning/befolkningstatistik/).

Swedish health care is public and tax funded. Health and demographic information on all inhabitants is recorded in a series of different healthcare registers. Linkage of data from these registers is possible using the 10-digit personal identification number automatically assigned to all Swedish residents [48].

Data sources

The Western Swedish Health Care Region (VEGA) was used to identify cases with gout. This register contains information back to 2000 about all healthcare contacts at inpatient and outpatient specialty clinics, as well as at primary care clinics, and includes the date of visit and diagnoses given by the treating physician according to the Swedish version of the International Statistical Classification of Diseases (ICD). Since 1997, the 10th version of ICD (ICD-10) is used in Sweden. The vast majority of patients with gout are treated by general practitioners.

The Swedish Prescribed Drug Register (PDR) (http://www.socialstyrelsen.se/register/halsodataregister/lakemedelsregistret) contains information about all prescribed drugs dispensed by Swedish pharmacies since July 2005.
This register was used to determine the exposure of patients and controls to treatment with diuretics within 6 months prior to first diagnosis of gout, as well as to support the obesity and hypertension diagnoses. The Anatomical Therapeutic Chemical Classification System (ATC codes) was used to identify the medical treatments (Additional file 1: Table S1).

Demographic data were obtained from Statistics Sweden (http://www.scb.se/en/), which holds data on immigration, emigration and residency. Data on education level were retrieved from the Longitudinal Integration Database for Health Insurance and Labor Market Studies (LISA), which is administered by Statistics Sweden and holds annual registers on all individuals 16 years of age and older.

Vital status on 31 December 2012 was determined via the Cause-of-death Register (https://www.socialstyrelsen.se/register/dodsorsaksregistret), which provides information on the date and cause(s) of death for all residents since 1961.

Study populations
We identified all patients who attended any inpatient, outpatient or primary care clinic between 1 January 2000 and 31 December 2012. In this study we included all patients who had received their first ICD-coded diagnosis corresponding to gout (Additional file 1: Table S1) between 1 January 2006 and 31 December 2012. This time period was chosen in order to be able to link our data to the PDR and to be able to define these cases as incident. Cases with a diagnosis of gout before that period, cases receiving ULT before gout diagnosis and cases aged < 20 years were excluded (Fig. 1). Up to five general population comparators, alive and without gout by the time of the index patients' first gout diagnosis were identified for each gout patient and matched by year of birth, sex and county from the population register held by Statistics Sweden.

Comorbidities and medication of interest
We classified comorbidities into two diagnostic categories: comorbidities which have been 'suggested to increase the SU level' and consequently increase the risk for clinical gout (psoriasis, transplantation, renal disease, use of diuretics, obesity and alcoholism); and ‘other comorbidities’, such as diabetes, hypertension, coronary heart disease (CHD), congestive heart failure (CHF), atrial fibrillation (AF), stroke, thromboembolism, PVD and chronic obstructive pulmonary disease (COPD), in which the causal relationship to urate levels and clinical gout is not clear. With the exceptions of hypertension and obesity (based on both ICD codes and/or ever previously dispensed prescription of antihypertensive or anti-obesity drugs respectively according to ATC codes in the PDR), comorbidities were defined as the presence of at least one visit to a physician in primary or specialized care with a corresponding ICD-coded diagnosis (Additional file 1: Table S1). Treatment with diuretics (including thiazide, loop and thiazide-related diuretics) was defined as having dispensed a prescription of these agents within 6 months prior to first diagnosis of gout.

Comparison by sex
We compared demographic characteristics and pattern of comorbidities separately in men and women, with their respective controls.

Statistical analysis
Data are expressed as mean ± SD for continuous variables and number and percentages for categorical variables. The prevalence of a specific comorbidity was calculated by dividing the number of subjects diagnosed with that comorbidity prior to the date of first gout diagnosis of the index patient as numerator (for both cases and controls) by the total number of patients with gout or controls as denominator. Prevalence ratios (PRs) and 95% confidence intervals (CIs) were used to estimate the association between gout and each coexisting medical condition. In a sensitivity analysis, only cases with two or more visits with an ICD-coded diagnosis of gout [49] were included and compared with their matched controls. In the sex-stratified analyses we compared both the crude and standardized prevalence for each comorbidity. Standardization was done by the indirect method, with the Swedish census population in 2012 as the standard population. Nonoverlapping 95% CIs were considered statistically significant for all comparisons. All analyses were conducted using SAS software, version 9.3 (SAS Institute Inc. Cary, NC, USA).

Results
Population
A total of 14,113 individuals who received their first ICD-coded gout diagnosis between 1 January 2006 and 31 December 2012 were identified and matched to 65,782 general population comparator subjects (Fig. 1). There were 4600 women and 9513 men matched to 22,052 and 43,730 controls, respectively (Table 1). Women were approximately 6 years older than men at the time of gout diagnosis and had lower education level (Table 1).

Prevalence of comorbidities in the study population
Comorbidities suggested to increase SU level
At the time of gout diagnosis, 59.1% of gout cases had at least one comorbidity of this category, which was 2.1-
fold higher than in controls (27.7%) (Table 1). Exposure to diuretics (43.7%), renal disease (11.8%) and obesity (10.4%) were the most frequent of these comorbidities in gout patients and were 2.3–2.7-fold more common in gout patients at diagnosis vs matched controls (Table 1). The proportions of individuals having undergone organ transplantation and those having diagnosed alcoholism and to a lesser extent psoriasis were also more common in gout patients compared to controls (Table 1).

**Other comorbidities**

At the time of gout diagnosis, the overall proportion of patients having at least one comorbidity of this category was 71.8% in comparison to 51.3% of the controls (Table 1). All cardiovascular diseases were both common and highly associated with gout at the time of gout diagnosis (Table 1), with hypertension being the most frequent in both gout patients (67.0%) and controls (44.3%) (Table 1).
Table 1: Demographic characteristics of the study population and prevalence (95% CI) of comorbidities in gout cases at the time of first diagnosis and statistical comparisons between all gout patients and controls

|                          | Gout cases         | Controls          | PR (95% CI) (total gout cases – total controls) | p value (total gout cases – total controls) |
|--------------------------|--------------------|-------------------|------------------------------------------------|---------------------------------------------|
|                          | Men (N = 9513)     | Women (N = 4600)  | Men (N = 43,730)                               |                                             |
| Age at diagnosis (years), mean (SD) | 65.3 (14.9)       | 71.1 (15.1)       | 67.2 (15.2)                                     |                                             |
|                          |                   |                   | 64.4 (14.6)                                     |                                             |
|                          |                   |                   | 70.7 (15.0)                                     |                                             |
|                          |                   |                   | 66.5 (150)                                      |                                             |
| Level of education, N (%) |                   |                   |                                                 |                                             |
| ≤ 9 years                | 3560 (37.4)        | 2169 (47.2)       | 15,531 (35.5)                                  |                                              |
|                          | 4047 (42.6)        | 1655 (36.0)       | 17,349 (39.7)                                  |                                              |
|                          | 1766 (18.6)        | 690 (15.0)        | 10,254 (23.5)                                  |                                              |
| 10–12 years              |                   |                   |                                                 |                                             |
|                          | 744(81.2)          | 81.2              | 76.6                                           |                                              |
|                          | 52.2               | 62.8              | 59.1                                           |                                              |
|                          |                   |                   | 25.7                                           |                                              |
|                          |                   |                   | 31.7                                           |                                              |
| Comorbidities, total (%) |                   |                   |                                                 |                                              |
| Psoriasis, PR (95% CI)   | 3.6 (3.3–4.0)      | 4.0 (3.4–4.6)     | 3.7 (3.4–4.1)                                  |                                               |
|                          | 1.1 (0.9–1.3)      | 1.2 (0.9–1.5)     | 1.1 (1.0–1.3)                                  |                                               |
|                          | 5.1 (4.6–5.5)      | 1.8 (1.5–2.2)     | 4.0 (3.7–4.3)                                  |                                               |
| Other comorbidities (%)  | 693                | 76.9              | 71.8                                           |                                              |
| Diabetes, PR (95% CI)    | 149 (14.1–15.7)    | 18.3 (17.1–19.6)  | 1.0 (15.4–16.7)                               |                                               |
|                          | Hypertension, PR (95% CI) | 645 (62.9–661)    | 72.3 (69.9–74.8)                              |                                               |
| Coronary heart disease, PR (95% CI) | 195 (18.6–204)    | 18.2 (170–195)    | 1.9 (184–198)                                 |                                               |
| Congestive heart failure, PR (95% CI) | 162 (16.1–178)    | 21.4 (201–22.8)   | 1.8 (177–191)                                 |                                               |
| Atrial fibrillation, PR (95% CI) | 186 (17.7–195)    | 19.0 (178–20.3)   | 1.8 (180–19.5)                                |                                               |
| Stroke, PR (95% CI)      | 83 (7.7–89)        | 9.4 (86–103)      | 8.7 (82–92)                                    |                                               |
| Thromboembolism, PR (95% CI) | 9.7 (9.1–104)     | 13.6 (126–147)    | 1.1 (105–116)                                 |                                               |
| Peripheral vascular disease, PR (95% CI) | 45 (4.1–50)      | 5.5 (48–62)       | 4.8 (45–52)                                    |                                               |
| Chronic obstructive pulmonary disease, PR (95% CI) | 49 (4.5–54)      | 6.5 (58–73)       | 5.5 (51–59)                                    |                                               |

CI: confidence interval, PR: prevalence ratio, SD: standard deviation, SU: serum urate
Comparison by sex

Crude prevalence At the time of first gout diagnosis, all comorbidities were more frequent in cases compared to controls both overall and stratified by sex (Table 1).

All comorbidities, except for alcoholism, renal disease and CHD, had higher point prevalence in women compared to men, with nonoverlapping 95% CIs for use of diuretics (53.4% vs 39.1%), obesity (12.2% vs 9.5%), diabetes (18.3% vs 14.9%), hypertension (72.3% vs 64.5%), CHF (21.4% vs 16.2%), thromboembolism (13.6% vs 9.7%) and COPD (6.5% vs 4.9%). In men, only diagnosed alcoholism (5.1% vs 1.8%) was significantly more common.

Age-standardized prevalence The higher age of women at diagnosis (71.1 years compared to 65.3 years in men) was taken into account in two separate analyses.

First, the PRs for comorbidities were calculated by sex for each comorbidity (Fig. 2) compared to age-matched controls. The pattern of PRs was overall similar for men and women, although there were slightly higher PRs (nonoverlapping 95% CIs) for men for diagnosed hypertension and use of diuretics, and for women with regard to diagnosed renal disease and diabetes compared to the opposite sex (Fig. 2).

Second, we compared the age-standardized prevalence of comorbidities in men and women with gout (Table 2). In these analyses, comorbidities suggested to increase SU levels did not differ substantially (overlapping 95% CIs) and were numerically similar in men and women, with the exception of a slightly higher prevalence (but overlapping 95% CIs) for diagnosed obesity and use of diuretics in women.

On the other hand, the age-standardized prevalence for other comorbidities such as CHD, CHF and AF was significantly higher in men (nonoverlapping 95% CIs) compared to that for women, whereas the age-standardized prevalence for thromboembolism and COPD was significantly higher in women (nonoverlapping 95% CIs).

Sensitivity analyses To assess the robustness of the results we also calculated the prevalence of the various comorbidities, defining gout by a stricter definition of having had two or more visits to a physician with gout over time. The prevalence of comorbidities when using the stricter case definition was overall similar to that in the main analyses (Additional file 2: Table S2).

Discussion In this large, population-based study of patients with gout, recruited from both primary and specialized health care, we found that both comorbidities suggested to increase SU level and other comorbidities were more common in gout cases vs population-based controls, both overall and for men and women separately. All
comorbidities, except for alcoholism, were or tended to be more frequent in women than in men at the time of first gout diagnosis. When standardizing for age, these sex differences were attenuated, and diagnoses of CVD were actually more prevalent in men. Since gout may be diagnosed several years after the first attack [50], both hyperuricemia and gout may have been present for a considerable time before and a causal relation to CVD or other comorbidities is not possible to deduce from the present study. Regarding occurrence of comorbidities suggested to increase SU level, there were only minor sex differences after age standardization, which suggests large similarities in the pathophysiologic pathways leading to gout in men and women.

The prevalence of some comorbidities in our study, such as hypertension, CHF, diabetes, PVD and renal disease, was higher than that in the study by Kuo et al. [43], despite the fact that both studies are register based, include a large group of patients and report occurrence of comorbidities at the time of first gout diagnosis. The prevalence of psoriasis, however, was almost the same in both studies. Possible explanations, apart from the different geographical setting, could be that the mean age of gout patients in our study was 5 years higher and that our study had a slightly higher proportion of women (32.6% vs 27.5%), who were found to have higher occurrence of associated comorbidities than men.

Other studies that have examined sex differences in occurrence of comorbidities by sex differ to some extent from ours. One previous study on established gout by Harrold et al. from 2017 [44] showed, in line with the present study, that women had higher prevalence of obesity, hypertension and diabetes mellitus and were more likely to take diuretics compared to men, although this study was based on a smaller sample of patients identified from an American network of rheumatologists. In another previous American study [45] based on 6133 patients diagnosed with gout as part of their health insurance plans, all evaluated comorbidities (obesity was not included) were more frequent in women with gout compared to men. On the other hand, these studies showed that women had higher prevalence of kidney disease compared to men, which is not confirmed in our study. One possible explanation could be that our study is conducted at the time of first diagnosis of gout, whereas the previous studies examined prevalent gout, and that the mean age of our male patients was 5 and 7 years higher respectively than in the two previous studies. There is also one small clinical study by De Souza et al. [47] based on only 58 patients that showed no differences in the occurrence of comorbidities between women and men, which could be explained by the small sample size of the study. We have also shown that thromboembolism and COPD were more frequent in

### Table 2

| Comorbidities suggested to increase SU level | Gout cases (N = 14,113) | 95% CI | Comorbidities | Gout cases (N = 14,113) | 95% CI |
|---------------------------------------------|------------------------|-------|---------------|------------------------|-------|
| | Men (N = 9513), prevalence (%) | Women (N = 4600), prevalence (%) | | | |
| Psoriasis | 3.7 | 2.8–4.5 | 3.3 | 2.6–4.1 |
| Organ transplantation | 1.3 | 0.8–1.8 | 1.8 | 0.9–2.6 |
| Renal disease | 8.2 | 7.4–9.0 | 8.3 | 6.8–9.8 |
| Use of diuretics | 21.9 | 20.9–22.8 | 24.1 | 22.7–25.6 |
| Obesity | 10.2 | 8.9–11.6 | 12.5 | 10.8–14.3 |
| Alcoholism | 5.5 | 4.7–6.3 | 3.5 | 2.1–4.8 |
| Other comorbidities | | | | |
| Diabetes | 8.7 | 8.1–9.3 | 9.9 | 8.9–10.9 |
| Hypertension | 40.1 | 38.6–41.6 | 39.4 | 36.9–41.9 |
| Coronary heart disease | 9.4 | 9.0–9.9 | 6.4 | 5.8–7.0 |
| Congestive heart failure | 7.7 | 7.3–8.1 | 6.6 | 6.0–7.1 |
| Atrial fibrillation | 9.0 | 8.4–9.5 | 6.0 | 5.4–6.5 |
| Stroke | 4.1 | 3.7–4.5 | 3.3 | 2.8–3.7 |
| Thromboembolism | 5.2 | 4.8–5.6 | 6.6 | 5.8–7.5 |
| Peripheral vascular disease | 2.1 | 1.9–2.3 | 2.1 | 1.7–2.5 |
| COPD | 2.4 | 2.1–2.6 | 3.1 | 2.6–3.5 |

CI confidence interval, COPD chronic obstructive pulmonary disease, SU serum urate
women with gout compared to men. The association between these comorbidities and gout has not been studied before. The higher prevalence in women might suggest some differences in pathophysiologic pathways or risk profile between men and women, but it is not possible to study the underlying mechanisms in the present study.

Regarding CVD, we found a higher occurrence in men compared to women, when adjusting for age. Current literature on risk for cardiovascular events in men and women with gout reports conflicting results. In line with the present study that showed higher prevalence of CHD and CHF in men, when we standardized for age, Krishnan et al. [26] showed that men with hyperuricemia had an increased risk for myocardial infarction in a controlled trial examining the efficacy of risk reduction in men at high risk for vascular events. Results from the Framingham study [25] showed an increased risk for CHD and angina in men with gout, but not in women, independently of other cardiovascular risk factors. Choi and Curhan [4] showed in a large prospective study that men with gout had higher overall mortality compared to men without gout. In contrast, De Vera et al. [51] in a population-based cohort showed higher risk for myocardial infarction in women compared to men, and Clarson et al. [34] in a population representative cohort in the UK showed that female patients with gout were at greater risk for any vascular event compared to men with gout. These discrepancies could be explained by differences between studies in study design, sample size and selection of the study population. Regarding potential explanatory mechanisms for higher frequency of CVD in men, we showed that other conventional risk factors for CVD, such as obesity, hypertension or diabetes, were not higher in men, although smoking and dyslipidemia could not be taken into account due to lack of data.

A previous study by Wright et al. [39] showed that obesity, use of diuretics and, to a lesser extent, renal disease had a significant influence on plasma urate concentrations and allopurinol daily maintenance dose. According to this study, dose requirements to achieve treatment goals for SU were found to increase by 2-fold to over 3-fold with increasing total body weight and were 1.25–2 times higher in those taking diuretics, whereas renal function had a relatively modest impact on the required allopurinol dose. Another study [40] suggests that the effect of decreased eGFR and diuretic use is explained by their ability to increase SU levels and not by any effect on the dose–response relationship between the given allopurinol dose and the change in urate levels. Considering that women in our study and previous studies [44] have a trend toward a higher prevalence of obesity and use of diuretics, factors that increase urate levels in serum, these comorbidities should be considered when initiating and adjusting ULT in women.

Some possible limitations should be acknowledged. The identification of gout patients was based on ICD codes, which may have led to some misclassification bias. However, according to a previous validation study [49], a more strict definition of gout requiring one or more visits with an ICD-coded gout diagnosis by a rheumatologist or two or more visits in primary care was found to have a high positive predictive value for fulfilling the various classification criteria for gout. The comorbidity pattern of gout cases in the present study was very similar to the comorbidity pattern of those fulfilling the stricter case definition (Additional file 2: Table S2), suggesting similar validity for both case definitions. Regarding definition of comorbidities, the validity of ICD codes in the Swedish national patient registry is generally very high [48], although not all diagnoses used in this study have been validated. There is, thus, a possible risk for underestimation of some comorbidities, in particular obesity and alcoholism, when ICD codes are used for definitions. However, there is no reason to believe that such underestimation would be of different magnitude in cases compared to controls and in women compared to men. Smoking, which is a major risk factor for CVD, could not be taken into account because of a lack of data. Finally, the study was performed in the western part of Sweden, which may hamper generalizability. However, according to previous reports, the sociodemographic distribution and healthcare seeking in this region are very similar to Sweden as a whole [52, 53].

This study has also several strengths. First, it is a population-based study, including all gout cases in the region, which reduces the risk of selection bias. Second, patients were identified from both primary and specialized health care, which covers all of the different phenotypes of gout, from mild to severe disease. Third, several unrelated independent data sources were used. For instance, case identification and information regarding medication or education level were retrieved from completely independent sources. Fourth, the study includes a large number of subjects with gout and controls, which generates statistically robust estimates for the occurrence of the various comorbidities.

Conclusions
This large, population-based study shows that all patients with gout have higher occurrence of many comorbid conditions at the time of first diagnosis,
compared to matched controls from the general population. The majority of these comorbidities are more common in women than in men with gout. In particular, the higher occurrence of diuretic use and obesity in women may need to be taken into account when initiating ULT.

Additional files

**Additional file 1**: Table S1. Definition of comorbidities based on ICD and/or ATC codes (DOCX 94 kb)

**Additional file 2**: Table S2. Demographic characteristics and prevalence (95% CI) of comorbidities for gout cases and controls, where cases were defined according to the strict definition of requiring ≥2 visits with a diagnosis of gout (DOCX 98 kb)

Abbreviations

AF: Atrial fibrillation; ATC: Anatomical Therapeutic Chemical Classification System; CHD: Coronary heart disease; CHF: Congestive heart failure; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; CVD: Cardiovascular disease; eGFR: Estimated glomerular filtration rate; ICD: International Statistical Classification of Diseases; LISA: Longitudinal Integration Database for Health Insurance and Labor Market Studies; MSU: Monosodium urate; PDR: Swedish Prescribed Drug Register; PR: Prevalence ratio; PVD: Peripheral vascular disease; SD: Standard deviation; SU: Serum urate; ULT: Urate lowering therapy; VEGA: Western Swedish Health Care Region

Funding

This study was supported by grants from The University of Gothenburg and The Swedish Rheumatism Association.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

All authors were involved in the conception and design of the study. LTHJ and MD contributed to the acquisition of the data. All authors contributed to the analysis and interpretation of the data and the accuracy of the analyses. All authors participated in the drafting of the manuscript or revised it critically for intellectual content. All authors approved the final version to be published.

Ethics approval and consent to participate

Ethical approval for the study was granted by the Ethical Review Board of Gothenburg, Sweden. Informed consent from the patients was not needed. Ethical approval for the study was granted by the Ethical Review Board of Gothenburg, Sweden. Informed consent from the patients was not needed.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 7 February 2018 Accepted: 18 April 2018

Published online: 01 June 2018

References

1. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(1):649–62.
2. Kuo CF, Yu KH, See LC, Chou UI, Tseng WY, Chang HC, et al. Elevated risk of mortality among gout patients: a comparison with the national population in Taiwan. Joint Bone Spine. 2011;78(6):577–80.
3. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010;49(1):141–6.
4. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894–900.
5. Hueskes BA, Roovers EA, Mantel-Teeuwisse AK, Janssen HJ, van de Lisdonk EH, Janssen M. Use of diuretics and the risk of gouty arthritis: a systematic review. Semin Arthritis Rheum. 2012;41(6):879–89.
6. Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol. 2014;66(1):185–96.
7. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90.
8. Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney. Pediatr Nephrol. 2014;29(6):999–1008.
9. Jurasechek SP, Kovell LC, Miller ER 3rd, Gelber AC. Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010. Semin Arthritis Rheum. 2013;42(6):551–61.
10. Prasad Sah OS, Qing YX. Associations between hyperuricemia and chronic kidney disease: a review. Nephrourol Mon. 2015;73(3):e27233.
11. Avram Z, Krishnan E. Hyperuricemia—where nephrology meets rheumatology. Rheumatology (Oxford). 2008;47(7):656–4.
12. Yu KH, Kuo CF, Luo SF, See LC, Chou UI, Chang HC, et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012;14(2):R83.
13. Feig DI. Serum uric acid and the risk of hypertension and chronic kidney disease. Curr Opin Nephrol. 2014;23(2):176–85.
14. Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritze E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28(9):2221–8.
15. Haslam DW, James WP. Obesity. Lancet. 2005;366(9492):1197–209.
16. Gheita TA, El-Fishawy HS, Nasrallah MM, Hussein H. Insulin resistance and metabolic syndrome in primary gout: relation to punched-out erosions. Int J Rheum Dis. 2012;15(6):521–5.
17. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11(5):974–9.
18. Neal DA, Tom BD, Gimson AE, Gibbs P, Alexander GJ. Hyperuricemia, gout, and renal function after liver transplantation. Transplantation. 2001;72(10):1689–91.
19. Schwab P, Lipton S, Kerr GS. Rheumatologic sequelae and challenges in organ transplantation. Best Pract Res Clin Rheumatol. 2010;24(3):329–40.
20. Stamp L, Ha L, Searle M, O’Donnell J, Frampton C, Chapman P. Gout in renal transplant recipients. Nephrolody (Carlton). 2006;11(4):367–71.
21. Merola JF, Wu S, Han J, Choi HK, Qureshi AA. Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis. 2015;74(8):1495–500.
22. Kwon HH, Kwon IH, Choi JW, Youn J. Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. Clin Exp Dermatol. 2011;36(5):473–8.
23. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363(9417):1277–81.
24. Tu HP, Tung YC, Tsai WC, Lin GT, Ko YC, Lee SS. Alcohol-related diseases and alcohol dependence syndrome is associated with increased gout risk: a nationwide population-based cohort study. Joint Bone Spine. 2017;84(2):189–96.
25. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41(3):237–42.
26. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheumatol. 2006;54(8):2688–96.
27. Gelber AC, Klag MJ, Mead LA, Thomas J, Thomas DJ, Pearson TA, et al. Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study. Arch Intern Med. 1997;157(13):1436–40.
28. Janssens HJ, van de Lisdonk EH, Bor H, van den Hoogen HJ, Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract. 2003;20(4):413–6.
29. Teng GG, Ang LW, Saag KG, Yu MC, Yuan JM, Koh WP. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis. 2012;71(6):924–8.
30. Seminog OJ, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford). 2013;52(12):2251–9.
31. Chen JT, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61(2):225–32.
32. Bos MJ, Koudstaal PJ, Hofman A, Witterman JC, Breeteler EM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37(6):1503–7.
33. Hozowa A, Folsom AR, Itohmi H, Nieto FJ, Rosamond WD, Shahar E. Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis. 2006;187(2):401–7.
34. Clarsen LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642–7.
35. Baker JF, Schumacher HR, Krishnan. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology. 2007;58(4):450–7.
36. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–24.
37. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout: Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–46.
38. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seck J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46(8):1372–4.
39. Wright DF, Duffull SB, Memman TR, Dalbeth N, Barclay MJ, Stamp LK. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016;81(2):277–89.
40. Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD, et al. Individualising the dose of allopurinol in patients with gout. Br J Clin Pharmacol. 2017;83(9):2015–26.
41. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125(7):679–87. e1
42. Primatapa P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskeletal Disord. 2011;12:103.
43. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210–7.
44. Harrold LR, Ezell CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, et al. Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskeletal Disord. 2017;18(1):108.
45. Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65(10):1368–72.
46. Yu LF. Some unusual features of gouty arthritis in females. Semin Arthritis Rheum. 1977;6(3):247–55.
47. De Souza A, Fernandes V, Ferrari AJ. Female gout: clinical and laboratory features. J Rheumatol. 2005;32(11):2186-8.
48. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekborn A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–67.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions